Status:
COMPLETED
A Study With Teduglutide (Revestive®) in Adults With Short Bowl Syndrome
Lead Sponsor:
Takeda
Conditions:
Short Bowel Syndrome
Eligibility:
All Genders
18+ years
Brief Summary
The main aims of the study are to assess the safety profile of teduglutide (Revestive®) as well as how many people with Short Bowl Syndrome experience a reduction of parenteral support when treated wi...
Eligibility Criteria
Inclusion
- Participants \>= 18 years of age diagnosed with intestinal failure due to SBS as a result of intestinal resection.
- SBS-IF participants treated with teduglutide according to Summary of Product Characteristics (SmPC).
- Patients who receive or have received teduglutide for at least six months at the date of inclusion (from treatment initiation to inclusion date, date of discontinuation, death for any cause or loss of follow-up).
- When required by the ethics committee of the center: participants who have signed the informed consent form (ICF) to participate in the study.
Exclusion
- \- Participants who do not meet the inclusion criteria.
Key Trial Info
Start Date :
January 26 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 24 2023
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT04883606
Start Date
January 26 2022
End Date
July 24 2023
Last Update
August 31 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Universitari de Bellvitge
L'Hospitalet de Llobregat, Barcelona, Spain, 08907